Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Program Helps Hepatitis C Patients
Uncategorized

Program Helps Hepatitis C Patients

By medwebNov 4, 2002
Share
Facebook Twitter Email

November 4, 2002

Program Helps Hepatitis C Patients

BOSTON— A new cognitive behavioral therapy strategy developed by Schering-Plough improves compliance among patients with hepatitis C (HCV) who are receiving the pegylated interferon-based combination therapy Peg-Intron® and Rebetol® (ribavirin), according to a Northwestern University study.

Steven L. Flamm, MD, associate professor of medicine and of surgery at The Feinberg School of Medicine and principal investigator on the study, presented his group’s findings today at the 53rd annual meeting of the American Association for the Study of Liver Disease.

In his presentation, Dr. Flamm showed that HCV patients enrolled in an aggressive side-effect management program including the Schering-Plough patient assistance program BeInCharge are less likely to stop taking Peg-Intron and Rebetol combination therapy in the first 12 weeks of therapy than patients who receive only routine supportive care by their physicians.

Study results also indicated that pegylated interferon-based combination therapy significantly improves physical- and mental health-related quality of life at weeks four and eight of the regimen.

“The next advancement in treatment may be some years down the road. Right now we need to maximize the current standard of care to get better results for patients,” Dr. Flamm said. “This study suggests that a proactive support program can actually contribute to the success of therapy and can therefore lead to increased cures for this often deadly infection.”

BeInCharge is designed to assist patients in managing side effects associated with HCV therapy through the use of educational materials and telephone support by nurses. To date, the program has enrolled more than 55,000 HCV patients.

Some 4 million Americans are infected with HCV, and approximately 70 percent of infected patients go on to develop chronic liver disease, according to the Centers for Disease Control and Prevention. HCV infection contributes to the deaths of an estimated 8,000–10,000 Americans each year.

Treatment for HCV-related disease is expected to exceed $13 billion in the United States for the years 2010 through 2019, according to a recent study.

Education
Share. Facebook Twitter Email

Related Posts

Honoring the PA Class of 2022

Jun 1, 2022

Celebrating Honors Day 2022

May 23, 2022

Taking a Second Look at Feinberg

Apr 21, 2022

Comments are closed.

Latest News

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Student Spearheads Ukraine Aid Efforts

Jun 27, 2022

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Combination Treatment May Improve Quality of Life in Kidney Cancer

Jun 23, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20220617_NM_0434
20220617_NM_0858
20220617_NM_0643
20220617_NM_0835
20220617_NM_0544
20220617_NM_0450
20220617_NM_0790
20220617_NM_0811
20220617_NM_0851
20220617_NM_0696
20220617_NM_0779
20220617_NM_0838

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.